Upload File

The top documents tagged [fda perspective]

Crossing the Quality Chasm Quality problems occur typically not because of failure of goodwill, knowledge, effort or resources devoted to health care,
Crossing the Quality Chasm Quality problems occur typically not because of failure of goodwill, knowledge, effort or resources devoted to health care,
215 views
1 FDA Perspective: FDA Evaluation of Point of Care Blood Glucose Meters Patricia Bernhardt, M.T.(ASCP), Scientific Reviewer Office of in Vitro Diagnostic
1 FDA Perspective: FDA Evaluation of Point of Care Blood Glucose Meters Patricia Bernhardt, M.T.(ASCP), Scientific Reviewer Office of in Vitro Diagnostic
217 views
Module 2 Final June 2007
Module 2 Final June 2007
1.005 views
Fda gutierrez slides[3]
Fda gutierrez slides[3]
443 views
1 FDA Perspective on Direct Acting Antiviral Trials Wendy Carter, D.O. Medical Officer Division of Antiviral Products US Food and Drug Administration The
1 FDA Perspective on Direct Acting Antiviral Trials Wendy Carter, D.O. Medical Officer Division of Antiviral Products US Food and Drug Administration The
216 views
D. Christopher Watts, Ph.D. Office of Pharmaceutical Science, CDER, FDA ASQ/FDC October 22, 2004 Process Analytical Technology (PAT)
D. Christopher Watts, Ph.D. Office of Pharmaceutical Science, CDER, FDA ASQ/FDC October 22, 2004 Process Analytical Technology (PAT)
232 views
U.S. FDA Perspective on Food Supplements/TM IKHLAS A. KHAN National Center for Natural Products Research, Department of Pharmacognosy and Research Institute
U.S. FDA Perspective on Food Supplements/TM IKHLAS A. KHAN National Center for Natural Products Research, Department of Pharmacognosy and Research Institute
215 views
1 Canine NSAIDs—What Dog Owners Should Know An FDA Perspective Dr. Carmela Stamper FDA Center for Veterinary Medicine
1 Canine NSAIDs—What Dog Owners Should Know An FDA Perspective Dr. Carmela Stamper FDA Center for Veterinary Medicine
217 views
Feldman 13 Nov 2007 1 Meetings with FDA Martha A. Feldman, RAC Drug & Device Development Co., Inc. UWE Biomedical Regulatory Affairs
Feldman 13 Nov 2007 1 Meetings with FDA Martha A. Feldman, RAC Drug & Device Development Co., Inc. UWE Biomedical Regulatory Affairs
216 views
Continuous Purity™ Marc Bisschops Tarpon Biosystems Inc. Integrated Continuous Biomanufacturing Castelldefels – Spain October 20 – 24, 2013 Technological,
Continuous Purity™ Marc Bisschops Tarpon Biosystems Inc. Integrated Continuous Biomanufacturing Castelldefels – Spain October 20 – 24, 2013 Technological,
220 views
NANOPARTICLES FOR DRUG DELIVERY: THE SMALLER, THE BETTER ? Gurny R., Pourtier M., Vargas A., Delie F. Department of Pharmaceutics and Biopharmaceutics
NANOPARTICLES FOR DRUG DELIVERY: THE SMALLER, THE BETTER ? Gurny R., Pourtier M., Vargas A., Delie F. Department of Pharmaceutics and Biopharmaceutics
223 views
1 FDA Perspective on Nanomaterial- Containing Products Nakissa Sadrieh, Ph.D. Associate Director for Research Policy and Implementation Office of Pharmaceutical
1 FDA Perspective on Nanomaterial- Containing Products Nakissa Sadrieh, Ph.D. Associate Director for Research Policy and Implementation Office of Pharmaceutical
214 views